Please login to the form below

Not currently logged in
Email:
Password:

MedImmune appoints head of research

Yong-Jun Liu to lead R&D at AstraZeneca biologics subsidiary

MedImmune Jong-Jun LiuAstraZeneca (AZ) has strengthened its research team by appointing leading academic Dr Yong-Jun Liu as head of research at its MedImmune subsidiary.

AZ has made of series of pipeline-boosting acquisitions in the past year, but the appointment of Dr Liu is a move to strengthen its existing R&D operations.

Dr Liu joins the company after an extensive career in academia, which most recently saw him serve as VP and chief scientific officer at the Baylor Research Institute and director of the Baylor Institute for Immunology Research.

He also served for a period as chair of the Department of Immunology at the University of Texas.

MedImmune focuses on the development of biologics and will look to benefit from Dr Liu's experience in immunology as it works to develop a portfolio of immunotherapies, including investigational cancer treatments.

Bahija Jallal, executive VP MedImmune, commented on the company's commitment to develop in-house research through strong leadership.

“Scientific leadership is our top priority,” said Jallal. “We are committed to hiring established leaders who will drive our research engine and progress our efforts to deliver valuable medicines to patients.”

18th November 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics